PortfoliosLab logo
Nanobiotix S.A. (NBTX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US63009J1079

CUSIP

63009J107

IPO Date

Dec 11, 2020

Highlights

Market Cap

$183.69M

EPS (TTM)

-$1.62

Total Revenue (TTM)

$9.29M

Gross Profit (TTM)

$9.29M

EBITDA (TTM)

-$23.24M

Year Range

$2.76 - $7.29

Target Price

$7.38

Short %

0.01%

Short Ratio

0.47

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Nanobiotix S.A.

Popular comparisons:
NBTX vs. SCHD NBTX vs. VT
Popular comparisons:

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

Nanobiotix S.A. (NBTX) returned 27.48% year-to-date (YTD) and -41.18% over the past 12 months.


NBTX

YTD

27.48%

1M

13.17%

6M

-4.47%

1Y

-41.18%

3Y*

-12.73%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.67%

1M

10.48%

6M

-1.79%

1Y

10.08%

3Y*

13.71%

5Y*

14.60%

10Y*

10.64%

*Annualized

Monthly Returns

The table below presents the monthly returns of NBTX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202521.43%0.72%1.99%-5.31%7.93%27.48%
20244.40%-17.76%4.00%-10.15%20.55%-28.98%8.40%10.70%-4.17%-27.65%-22.36%-11.15%-60.58%
202316.24%-17.49%0.14%-39.29%114.02%10.70%52.07%18.55%-4.27%-22.86%-16.96%29.88%98.37%
2022-5.56%-1.44%-1.33%-20.70%-11.36%-27.34%-38.95%71.98%-11.28%11.86%-0.25%-7.09%-54.69%
20211.03%-0.32%-9.48%2.86%10.67%-19.51%6.87%-14.44%-9.84%-8.19%-18.70%-4.48%-50.91%
2020-2.83%-2.83%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of NBTX is 17, meaning it’s performing worse than 83% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of NBTX is 1717
Overall Rank
The Sharpe Ratio Rank of NBTX is 1919
Sharpe Ratio Rank
The Sortino Ratio Rank of NBTX is 1515
Sortino Ratio Rank
The Omega Ratio Rank of NBTX is 1818
Omega Ratio Rank
The Calmar Ratio Rank of NBTX is 1515
Calmar Ratio Rank
The Martin Ratio Rank of NBTX is 2020
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Nanobiotix S.A. (NBTX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Nanobiotix S.A. Sharpe ratios as of May 23, 2025 (values are recalculated daily):

  • 1-Year: -0.59
  • All Time: -0.21

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Nanobiotix S.A. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Nanobiotix S.A. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Nanobiotix S.A.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Nanobiotix S.A. was 89.94%, occurring on May 1, 2023. The portfolio has not yet recovered.

The current Nanobiotix S.A. drawdown is 81.41%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-89.94%Jan 21, 2021573May 1, 2023
-15.41%Dec 18, 20207Dec 29, 202014Jan 20, 202121
-6.07%Dec 14, 20201Dec 14, 20202Dec 16, 20203

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Nanobiotix S.A. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Nanobiotix S.A., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -7.5%.


-0.50-0.40-0.30-0.20-0.100.00Jan 03Jan 10Jan 17Jan 24Jan 31Feb 07Feb 14Feb 21Feb 28Mar 07Mar 14Mar 21Mar 28
-0.52
0
Actual
Estimate

Valuation

The Valuation section provides an overview of how Nanobiotix S.A. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for NBTX relative to other companies in the Biotechnology industry. Currently, NBTX has a P/S ratio of 3.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for NBTX in comparison with other companies in the Biotechnology industry. Currently, NBTX has a P/B value of 65.0. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items